Quote · The Peter Attia Drive
#397 ‒ Endometriosis and adenomyosis: diagnosis, fertility, reproductive aging, and emerging treatments | Renato Tomioka, M.D., Ph.D.
Where this was said
The funding gap in endometriosis research: disease burden, economic impact, and growing awareness
At 1:20:10 · chapter starts 1:20:03
In a brief but pointed section, Tomioka quantifies the research funding imbalance that he sees as the structural root of the diagnostic delay problem. The NIH invests approximately 15 times more on diabetes than endometriosis. [1] — Renato Tomioka "NIH invests 15x more on diabetes than endo: The NIH invests approximately 15 times more money on diabetes research than on endometriosis re…" 1:20:10 Yet the per-patient annual economic burden is higher for endometriosis ($16,000) than diabetes ($12,000), mostly because two-thirds of the endometriosis cost is productivity loss — missed work, missed school, missed careers. Peter asks why, and Tomioka's answer is characteristically direct: the disease has only recently begun to be taken seriously, mirroring the decades-long neglect of menopause research before recent public and clinical momentum. Documentaries, celebrity advocacy, and clinical guideline changes are beginning to shift the landscape.
The NIH invests approximately 15 times more money on diabetes research than on endometriosis research, despite endometriosis costing more per patient per year.
